A clinical-stage biotechnology company

PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.


PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.

PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy, and at François Baclesse center.


Backed by international investors

PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, Anaxago, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and by Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).

Our partners

logo seventure
Logo Italian angels
Logo Doorway
Logo Anaxago
Logo I&I prague
Les business angels des grandes écoles
institut Marie Curie
Gustave Roussy
Centre de lutte contre le cancer
Sorbonne université

Our partners